Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Renal Lesions: a Prospective, Blinded Study
Radiofrequency ablation (RFA) is an increasingly popular therapy option for treating small
kidney cancer, especially for patients who are not ideal candidates for traditional surgery.
Currently, follow-up after this procedure involves the patient having several CT scans (or
MRI scans in some cases) over time to monitor for possible cancer recurrence. However, there
are risks associated with the radiation exposure from CT scans and other risks, such as
adverse events from the contrast media used in these scans. This study will therefore
investigate whether a different technique, contrast-enhanced ultrasound (CEUS), can be an
effective tool for follow-up monitoring of kidney cancer patients who have undergone RFA by
comparing the results of their standard follow-up CT scans (or MRIs if applicable) with the
results of CEUS. If CEUS is found to be just as effective as CT scans or MRIs in detecting
kidney cancer recurrence, this technique could potentially become the new standard of care
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society